NEW ORLEANS — Patients with dry eye disease saw improvements in symptoms and signs after treatment with varenicline nasal spray, according to a study presented at the American Academy of Ophthalmology meeting.
Marjan Farid, MD, said Tyrvaya (varenicline solution, Oyster Point Pharma), formerly known as OC-01, is a cholinergic agonist that leads to an increase in basal tear production with rapid onset.
Researchers randomly assigned 758 patients with a Schirmer’s score of less than 10 mm into one of three groups: 0.03 mg OC-01, 0.06 mg OC-01 or vehicle control. (Read more...)